A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery

Summary

This study develops a brain-targeted nanocarrier by adding a neurotoxin-derived peptide to red-blood-cell membrane-coated nanoparticles. The blood-brain barrier limits entry of many therapeutics, so the investigators used D-CDX, a peptide derived from candoxin that binds nicotinic acetylcholine receptors on brain endothelial cells. They incorporated the peptide onto the membrane-coated particle surface through a method designed to preserve both the complex functions of the natural membrane and the peptide's receptor-binding activity. The modified particles showed enhanced brain targeting in cell-based assays and in vivo. In a mouse glioma model, doxorubicin carried by D-CDX-modified particles produced greater therapeutic efficacy and markedly lower toxicity than the non-targeted drug formulations described in the abstract. The principal result supports modular functionalization of membrane-coated nanocarriers for crossing or engaging the brain vascular interface, with potential applicability beyond the red-blood-cell model. Limitations include the absence of quantitative brain exposure, tumor response, survival, toxicity, and sample-size data. Receptor specificity, transport mechanism, peptide immunogenicity, off-target distribution, repeated dosing, and comparison with other brain-delivery systems are not detailed, and no human blood-brain-barrier or clinical evidence is reported.